It is no longer nice-to-have - it is happening
Cardiovascular outcomes after initiating GLP-1 receptor agonist or basal insulin for the routine treatment of type 2 diabetes: a region-wide retrospective study
Omar-Hmeadi M, Lund PE, Gandasi NR, Tengholm A, Barg S (2020) Paracrine control of -cell glucagon exocytosis is compromised in human type-2 diabetes
2022 JAMA Internal Medicine meta-analysis: pooling 76 randomised controlled trials, GLP-1 receptor agonist use was associated with a relative risk of 1.37 for biliary disease compared with placebo or other treatments
Si ve alguna reaccin, lvese inmediatamente con agua fra: el 85% de las irritaciones menores se resuelven dentro de las 2 horas de la eliminacin
Fasting glucose, HbA1c, liver function, kidney function, and lipid panels inform your provider's decision on safe starting doses, monitoring frequency, and any dose adjustments